Evidence map›Paper›PMID 37238657›Full record

ReviewBiomolecules2023

Role of Angiotensin II in Cardiovascular Diseases: Introducing Bisartans as a Novel Therapy for Coronavirus 2019.

Jordan Swiderski, Laura Kate Gadanec, Vasso Apostolopoulos, Graham J Moore, Konstantinos Kelaidonis, John M Matsoukas, Anthony Zulli

Open access · goldAbstract readReview
In one paragraph

Review in Biomolecules, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Jordan SwiderskiInstitute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia.ORCID 0000-0002-3613-2406
Laura Kate GadanecInstitute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia.ORCID 0000-0002-4801-8061
Vasso ApostolopoulosInstitute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia.ORCID 0000-0001-6788-2771
Graham J MoorePepmetics Incorporated, 772 Murphy Place, Victoria, BC V8Y 3H4, Canada.
Konstantinos KelaidonisNewDrug PC, Patras Science Park, 26500 Patras, Greece.
John M MatsoukasInstitute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia.ORCID 0000-0001-5554-2964
Anthony ZulliInstitute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia.
Victoria University · AUUniversity of Calgary · CAAustralian Institute for Musculoskeletal Science · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular diseases (CVDs) are the main contributors to global morbidity and mortality. Major pathogenic phenotypes of CVDs include the development of endothelial dysfunction, oxidative stress, and hyper-inflammatory responses. These phenotypes have been found to overlap with the pathophysiological complications of coronavirus disease 2019 (COVID-19). CVDs have been identified as major risk factors for severe and fatal COVID-19 states. The renin-angiotensin system (RAS) is an important regulatory system in cardiovascular homeostasis. However, its dysregulation is observed in CVDs, where upregulation of angiotensin type 1 receptor (AT

Indexed as

Cardiovascular DiseasesCOVID-19Angiotensin-Converting Enzyme InhibitorsAngiotensin IIAngiotensin Receptor AntagonistsHumansAngiotensin-Converting Enzyme InhibitorsAngiotensin IIAngiotensin Receptor Antagonistsangiotensin-converting enzyme 2angiotensin IIbisartanscardiovascular diseasescoronavirus 2019renin–angiotensin systemsevere acute respiratory syndrome coronavirus 2

Identifiers

PMID37238657
PMCPMC10216788
OpenAlexW4368405349

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.